2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC)

NANJING,China and GAITHERSBURG,Md.,Dec. 9,2024 -- TransThera Sciences Nanjing,Inc. (the "TransThera")announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to discuss the clinical study of tinengotinib in combination with atezolizumab (Tecentriq®)in biliary tract carcinoma (BTC).

Title:Tinengotinib (TT-00420) in Combination with Atezolizumab in Chinese Patients with Biliary Tract Carcinoma (BTC): Efficacy and Safety Results from a Phase Ib/II Study

Poster number: 140P

Immune-checkpoint inhibitor (ICI) combined with chemotherapy have been approved as first-line therapy for BTC. However,no standard of care has been established after first-line treatment and the survival of the patients is short,there is a huge unmet clinical need. Tinengotinib is a novel multi-kinase inhibitor. It may play a role of synergistic effect when combined with ICI. The efficacy and safety data of tinengotinib in combination with atezolizumab in Chinese BTC patients has been explored in a phase Ib/II study.

Results:

As of September 26,2024,a total of 31 heavily pretreated advanced BTC patients were enrolled and treated with tinengotinib plus atezolizumab. 71.0% were priorly treated with at least one immunotherapy.

Promising efficacy:

A total of 20 intrahepatic cholangiocarcinoma patients were efficacy evaluable. The objective response rate (ORR) and disease control rate (DCR) were 25.0% and 80.0%,the median progression free survival (mPFS) reached 8.77 months and the 12-month overall survival (OS) rate was 70.1%.

A total of 28 cholangiocarcinoma patients were efficacy evaluable. The ORR and DCR were 25.0% and 75.0%,the mPFS reached 5.72 months and the 12-month OS rate was 64.8%.

All 31 BTC patients were efficacy evaluable. The ORR and DCR were 22.6% and 74.2%,the mPFS reached 4.11 months and the 12-month OS rate was 61.8%.

Similar efficacy was observed regardless of prior ICI(s) therapy.

Good safety and tolerability:

No DLT was observed in the dose escalation phase.

The combination therapy was generally well tolerated in heavily pre-treated BTC patients.

These encouraging results suggest the combination therapy may have synergistic effect in treating some solid tumor such as BTC,and support the further exploration to evaluate the safety and efficacy of tinengotinib plus ICI in BTC patients who were previously treated with or without ICI therapy.

About Tinengotinib

Tinengotinib is an internally discovered,global phase III multi-kinase inhibitor that exerts antitumor effects by targeting FGFRs and VEGFRs,mitotic kinases Aurora A/B and Janus kinases (JAK). Ongoing clinical trials in the US and China have revealed the potential oftinengotinib to be efficacious in various solid tumors. It was granted the Orphan Drug Designation (ODD) and Fast Track Designation (FTD) by the FDA for the treatment of CCA,the Breakthrough Therapy Designation (BTD) by NMPA in China,the Orphan Drug Designation (ODD) for the treatment ofbiliary tract cancer by EMA.

About TransThera

TransThera is a clinical demand-oriented,registrational clinical-stage biopharmaceutical company focusing on discovering and developing innovative small molecule therapies for oncology,inflammatory and cardiometabolic diseases. Further aided by in-depth study of translational medicine and drug design,TransThera aims to develop first-in-class or best-in-class drug candidates strategically positioned to meet urgent clinical needs on a global scale. For more information,please visit www.transthera.com

Tecentriq® (atezolizumab) is a registered trademark of Genentech,a member of the Roche Group.

Forward-looking statements

This news contains forward-looking statements that involve risks,uncertainties,and assumptions. If risks or uncertainties ever materialize or the assumptions prove incorrect,our actual results may differ from those expressed or implied by such forward-looking statements. All statements other than statements of historical facts could be deemed forward-looking,including,but not limited to,any statement of the plans,strategies,and objectives of management for future operations,including but not limited to our clinical development and commercialization plans; any projections of financial information; any statements about historical results that may suggest trends for our business; any statements of expectation or belief regarding future events,potential markets or market size,technology developments,our product pipeline,clinical data,results or practices or the implications thereof,enforceability of our intellectual property rights,competitive strengths or our position within the industry; and any statements of assumptions underlying any of the items mentioned.